Glaukos Corporation has received $-0.01 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 6 Financial Advisor in the Stock Trading Firms. Among 6 Analysts, Bottom line EPS Estimate for the current quarter is $-0.07 while the top line estimate is $0.06 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 88.1%.
Glaukos Corporation reported better than expected with a surprise EPS of 400% or $0.04 during its most recent quarterly earnings. The Actual EPS was $0.03 compared to the Estimated EPS of $-0.01.
In the last quarter, Glaukos Corporation reported Annual Earnings of $0.03. Based on the filings, last years Annual Earnings was, $-2.13. In the last Quarter, GKOS reported a surprise Earnings per Share of 400% . The consensus estimate for current quarter is $-0.01 and for the current fiscal year, the estimate is $0.12. For the Next fiscal year, the estimate is $0.23 based on the consensus.
Glaukos Corporation (NYSE:GKOS) : On Tuesday heightened volatility was witnessed in Glaukos Corporation (NYSE:GKOS) which led to swings in the share price. The stock opened for trading at $38.2 and hit $41.42 on the upside , eventually ending the session at $41.22, with a gain of 8.33% or 3.17 points. The heightened volatility saw the trading volume jump to 1,305,748 shares. The 52-week high of the share price is $41.42 and the company has a market cap of $1,383 million. The 52-week low of the share price is at $14.25 .
Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California.